Translated material
In the center of Chumakov, they plan to release only 6 million doses of Kovivak before the end of the year
Developers of the Kovivak vaccine Center named after M.P. Chumakov was told in an interview with Medusa (the publication was included in the register of media-foreign agents.-The Bell) that by the end of the year it is planned to release 5-6 million units of the drug-this is half the previous forecasts of the government. Briefly retelling the most important thing from the conversation of scientists with journalists.
Now in the center of Chumakov, one million doses for supplying to civilian circulation are already ready - they will be released in late June. At the current capacities, the center plans to release only 5-6 million doses before the end of the year. Earlier, the Minister of Industry and Trade of the Russian Federation Denis Manturov predicted that in 2021 the Chumakov Center will produce at least 10 million drugs. At the same time, the developers of Kovivak added that they were waiting for a new, “sufficiently powerful equipment that should come to us in July” - if it really becomes available, the volumes of the vaccine will be increased to 60 million a year.
The Kovivak vaccine will now be tested in the third stage of clinical research - a group of volunteers will be 32 thousand people. According to the developers, the peculiarity of the current testing is that all participants in the test will be injected with a real vaccine, and not a placebo-since in the current epidemiological conditions "to conduct placebo-controlled studies of this volume is unethical." The third phase of testing will be a year.
The developers assure that despite the fact that the third phase of clinical trials has not been completed, the Chumakov center is confident in the effectiveness and safety of the vaccine. For example, all the monkeys on which the “covivak” was tested has formed a sufficient level of neutralizing antibodies, which remained stable for a long time.
Although, in terms of the method of working, the Kovivak vaccine is similar to some foreign competitors - for example, Chinese Sinovak and Sinofarm - the Russian drug is distinguished by the coronavirus with a strain of coronavirus. Chinese vaccines closer to the Chinese strain, and the Chumakov drug is made on the basis of the European D614G strain.
In the center of Chumakov, the fears of people retold by journalists also responded that the murdered virus used in the vaccine could then come to life in the bodies of the vaccinated. According to the developers, the virus is killed by a chemical substance-beta-propiolactone. To verify whether the virus is inactivated, scientists plant the virus on the culture where coronavirus grew up - and fix that "it does not grow there (more)." “(This. - The Bell) 100 % accuracy. We control this parameter about nine times, ”the scientists said.
Back in March 2021, “Open Media” noted that it was the Kovivak vaccine that many Russians are waiting for more than others - the drug was made on the basis of the murdered virus (this is the most well -studied approach), and not on the basis of adenoviruses (used in “satellite V” and “Epivacia”). Demand for Kovivak now really exceeds the proposal - on the website of the Mayor of Moscow it is already indicated that the record is suspended to vaccinate with this drug. Ilya Yasny, the head of the scientific examination of the Inbio Ventures Venture Fund, at the same time told Kommersant that he did not understand the excitement around Kovivak, since there is still no evidence of his effectiveness. “The conviction of people is that this vaccine is effective and safe, is based on rumors on the fact that this type of drug is more traditional. Here is a very big question: how exactly is the vaccine inactivated? You can underinactivate it and get a dangerous drug, or you can inactivate it too much, and then it will not be effective, ”the expert explained.